|
Intismeran autogene Clinical Trials
5 actively recruiting trials across 5 locations
No change since May 2026
Also known as: V940, mRNA-4157
Pipeline
Phase 2: 3Phase 3: 2
Top Sponsors
- Merck Sharp & Dohme LLC5
Indications
- Cancer5
- Lung Cancer3
- Carcinoma in Situ1
- Non-Muscle Invasive Bladder Neoplasms1
- Squamous Non-small-cell Lung Cancer1
Anchorage, Alaska1 trial
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Alaska Oncology and Hematology ( Site 0039)
Phase 3
Gilbert, Arizona1 trial
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Banner MD Anderson Cancer Center ( Site 0181)
Phase 3
Springdale, Arkansas1 trial
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Highlands Oncology Group ( Site 4042)
Phase 2
Bakersfield, California1 trial
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Michael G Oefelein Clinical Trials ( Site 0138)
Phase 2
Tampa, Florida1 trial
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Moffitt Cancer Center ( Site 0021)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.